Details for Patent: 7,846,961
Which drugs does patent 7,846,961 protect, and when does it expire?
Patent 7,846,961 protects PRESTALIA and is included in one NDA.
This patent has thirty patent family members in twenty-seven countries.
Summary for Patent: 7,846,961
| Title: | α crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | α-crystalline form of the compound of formula (I): characterized by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as inhibitors of angiotensin I converting enzyme. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Gérard Coquerel, Loïc Lefebvre, Jean-Claude Souvie, Pascale Authouart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Les Laboratoires Servier SAS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US12/224,369 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,846,961 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 7,846,961: Perindopril Arginine Alpha-Crystal Claims, Scope, Expiration and Patent LandscapeU.S. Patent No. 7,846,961 protects a specific alpha-crystalline form of the L-arginine salt of perindopril, a solvent-mediated process for producing that form, pharmaceutical compositions containing it, and its use in treating hypertension and heart failure. The patent is primarily a solid-state and manufacturing patent, not a broad patent on perindopril or ACE inhibition. The central enforceable asset is claim 1, which defines the product through powder X-ray diffraction peaks at approximately 4.5°, 7.9° and 13.5° 2θ. Claims 2 and 3 provide narrower diffraction-based versions. Claims 4 and 5 cover selected crystallization processes. Claims 6 through 9 extend protection to formulations and therapeutic use. What does U.S. Patent 7,846,961 protect?The patent protects four related subject-matter categories:
The patent does not claim:
The scope therefore turns on the identity of the solid form and, for process claims, the exact manufacturing route. What is the key product claim in Patent 7,846,961?Claim 1 covers:
This is a product-by-form claim. It does not require a particular manufacturing process. A product can infringe claim 1 even if it was made by a process different from the process recited in claim 4, provided the resulting material has the claimed structural characteristics. The claim has three material limitations:
The phrase “essentially” gives the claim some tolerance for experimental variation, peak intensity differences and additional minor peaks. It does not eliminate the need to show that the accused material has the defining diffraction pattern. How do claims 1, 2 and 3 differ?Claims 2 and 3 are narrower dependent claims.
Claim 3 lists diffraction lines at approximately 4.52°, 7.94°, 12.152°, 13.480°, 14.029°, 14.948°, 15.873°, 17.531°, 18.787°, 19.579°, 20.635°, 22.616°, 23.367°, 23.807°, 24.434°, 27.148° and 28.214° 2θ. The detailed intensity table strengthens identification of the claimed form but can also create a narrower infringement target. Minor differences caused by instrument calibration, sample preparation, crystallinity, preferred orientation or impurity content may become material in a claim-construction dispute. What formulations are protected by Patent 7,846,961?Claim 6 covers a pharmaceutical composition containing the claimed alpha-crystalline perindopril arginine with one or more pharmaceutically acceptable, inert, non-toxic carriers. The claim is composition-focused. It does not require a particular excipient, dosage form or route of administration. It can potentially reach tablets, capsules or other oral dosage forms if the claimed crystalline salt is present. Claim 7 adds a diuretic. Claim 8 narrows that combination to indapamide. The indapamide limitation is commercially relevant because it corresponds to the fixed-dose antihypertensive combination marketed with perindopril arginine in products such as Prestalia. The formulation claims do not independently protect:
Does the patent cover the manufacturing process?Yes. Claim 4 covers a process in which perindopril is dissolved in water with L-arginine, followed by addition of:
The resulting crystals are filtered, washed and dried. Claim 5 is narrower. It requires methylcyclohexane as the apolar solvent and dimethyl sulfoxide as the polar solvent.
A manufacturer can avoid literal infringement of claims 4 and 5 by using a different crystallization route, such as a different solvent system, antisolvent, temperature profile or isolation sequence. That alternative process would not necessarily avoid claims 1 through 3 if it produces the claimed alpha form. How strong is the product-form patent claim?The product claims have meaningful commercial value because they can cover the active solid form regardless of the manufacturing route. Their strength depends on four technical questions:
Claim construction and proofAn infringement case would likely require:
A product containing a mixture of the alpha form and another form may still raise infringement issues if the alpha form is present in the accused material. The result would depend on the claim language, the evidentiary record and any applicable prosecution-history limitations. Validity pressure pointsThe principal validity issues are likely to be:
A prior-art reference that discloses perindopril arginine without identifying the claimed alpha form would not necessarily anticipate claims 1 through 3. A reference that discloses the same PXRD peaks, or necessarily produces the same form, would present a stronger anticipation case. When did U.S. Patent 7,846,961 expire?The patent was granted on December 7, 2010. Its earliest priority date is reported as December 19, 2003. The ordinary patent-term endpoint is December 19, 2024, subject to any patent-term adjustment, terminal disclaimer or other term calculation reflected in USPTO records.
The key commercial consequence is that the patent is no longer a normal forward-looking U.S. launch barrier after its expiration date. It may still matter for historical Paragraph IV litigation, damages analysis, past sales, license interpretation and foreign counterparties with different expiration dates. What is the Orange Book status of Patent 7,846,961?The patent is relevant to FDA-approved perindopril arginine products, particularly fixed-dose perindopril arginine and amlodipine products. Orange Book significance depends on the specific reference-listed drug and the patent-listing history maintained by FDA. The regulatory distinction is important:
An ANDA applicant could address a listed patent through Paragraph IV certification, arguing that the patent is invalid, unenforceable or will not be infringed. A Paragraph IV notice can trigger Hatch-Waxman litigation and a 30-month stay of approval under the conditions specified in the Federal Food, Drug, and Cosmetic Act. The stay does not extend an expired patent term. Which companies could challenge the patent?Potential challengers are manufacturers seeking approval for:
The relevant challenger set includes generic drug companies with cardiovascular portfolios and contract manufacturers supplying ANDA sponsors. Publicly identifying a definitive challenger requires linking an ANDA, Paragraph IV notice or patent litigation docket to the specific listed patent. A generic applicant may pursue one of three technical strategies:
What patent litigation and settlement issues matter?A Paragraph IV case involving this patent would likely focus on whether the proposed product contains the patented alpha form. The technical record would be central. FDA approval alone would not resolve the patent question. Key litigation questions include:
Settlement terms could include a licensed entry date, a covenant not to sue, a manufacturing restriction, a polymorph specification or a conversion date tied to patent expiration. Hatch-Waxman settlements may also raise Federal Trade Commission review issues, particularly where the branded company provides value in exchange for delayed generic entry. The claims supplied here do not establish the terms or existence of any particular settlement. How does this patent compare with broader perindopril patents?Patent 7,846,961 occupies a later and narrower position in the perindopril lifecycle.
The patent is strongest against a competitor using the same alpha-crystalline perindopril arginine material. It is weaker against a competitor that can develop, characterize and manufacture a different solid form without conversion to the patented form. Does the patent create biosimilar risk?No. Perindopril arginine is a small-molecule active pharmaceutical ingredient. The relevant FDA pathway is an ANDA, not a biosimilar application under the Public Health Service Act. The principal regulatory risks are:
The absence of biosimilar risk does not eliminate manufacturing barriers. A competing manufacturer must still establish a reproducible, stable and regulatory-compliant form of perindopril arginine. What geographic coverage does the patent provide?U.S. Patent 7,846,961 provides rights only in the United States. Foreign protection depends on national or regional counterparts derived from the same patent family. A global freedom-to-operate review should separately examine:
Expiration dates can differ because of national filing dates, patent-term adjustments, supplementary protection certificates and local prosecution history. A U.S. expiration does not establish the status of foreign family members. What manufacturing and intellectual-property barriers remain after expiration?After U.S. expiration, the patent no longer blocks commercial manufacture based solely on its claims. Technical barriers remain:
The most important post-expiration distinction is between patent clearance and development feasibility. A company may be free to make perindopril arginine but still need to solve form-control and regulatory comparability problems. Key Takeaways
FAQs About U.S. Patent 7,846,961Is perindopril erbumine covered by Patent 7,846,961?Generally, no. The claims are directed to the L-arginine salt of perindopril, not perindopril erbumine. Can a generic use a different polymorph of perindopril arginine?Potentially. A different polymorph may avoid claims 1 through 3, but the manufacturer must confirm that the material does not convert into the claimed alpha form during processing, storage or administration. Does claim 4 cover every process that produces alpha-crystalline perindopril arginine?No. Claim 4 is limited to the specified aqueous and mixed-solvent process elements. Claims 1 through 3 are product claims and may apply regardless of the manufacturing process. Is an indapamide combination independently blocked by the patent?Only if the composition contains the claimed alpha-crystalline perindopril arginine and satisfies the applicable composition claim. Indapamide alone is not the protected subject matter. Can a company launch after December 19, 2024?The expiration of this patent removes its forward-looking U.S. barrier, but launch requires review of other unexpired patents, FDA requirements, exclusivity, labeling restrictions and any applicable litigation or settlement obligations. References
More… ↓ |
Drugs Protected by US Patent 7,846,961
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adhera | PRESTALIA | amlodipine besylate; perindopril arginine | TABLET;ORAL | 205003-001 | Jan 21, 2015 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF HYPERTENSION | ⤷ Start Trial | ||
| Adhera | PRESTALIA | amlodipine besylate; perindopril arginine | TABLET;ORAL | 205003-002 | Jan 21, 2015 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF HYPERTENSION | ⤷ Start Trial | ||
| Adhera | PRESTALIA | amlodipine besylate; perindopril arginine | TABLET;ORAL | 205003-003 | Jan 21, 2015 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF HYPERTENSION | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,846,961
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| France | 06 01748 | Feb 28, 2006 |
| PCT Information | |||
| PCT Filed | February 26, 2007 | PCT Application Number: | PCT/FR2007/000335 |
| PCT Publication Date: | September 07, 2007 | PCT Publication Number: | WO2007/099217 |
International Family Members for US Patent 7,846,961
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2007220435 | ⤷ Start Trial | |||
| Brazil | PI0708278 | ⤷ Start Trial | |||
| Canada | 2644467 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
